Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with proven advanced and progressive renal cell carcinoma (RCC) of the clear cell type.~2. At least one evaluable lesion \< 5 cm.~3. Karnofsky performance status ≥ 70%.~4. Laboratory values obtained \< 14 days prior to registration:~   * White blood cells (WBC) ≥ 3.5 × 10\^9/L~  * Platelet count ≥ 100 × 10\^9/L~  * Hemoglobin ≥ 6 mmol/L~  * Total bilirubin ≤ 2 × upper limit of normal (ULN)~  * Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN (\< 5 × ULN if liver metastases present)~  * Serum creatinine ≤ 2 × ULN~5. Negative pregnancy test for women of childbearing potential (urine or serum).~6. Age over 18 years.~7. Ability to provide written informed consent.~Exclusion Criteria:~1. Known metastases to the brain.~2. Untreated hypercalcemia.~3. Metastatic disease limited to the bone.~4. Pre-exposure to murine/chimeric antibody therapy.~5. Chemotherapy, external beam radiation or immunotherapy within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures was allowed, when unirradiated, evaluable lesions were present elsewhere.~6. Cardiac disease with New York Heart Association classification of III or IV.~7. Subjects who were pregnant, nursing or of reproductive potential and were not practicing an effective method of contraception.~8. Any unrelated illness, e.g., active infection, inflammation, medical condition or laboratory abnormality, that in the judgement of the investigator would have significantly affected the subject's clinical status.~9. Life expectancy \< 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1, 30 mCi/m^2 177-Lu-DOTA-cG250 (Type: EXPERIMENTAL): Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 30 mCi/m\^2 of 177-Lu.
- Cohort 2, 40 mCi/m^2 177-Lu-DOTA-cG250 (Type: EXPERIMENTAL): Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 40 mCi/m\^2 of 177-Lu.
- Cohort 3, 50 mCi/m^2 177-Lu-DOTA-cG250 (Type: EXPERIMENTAL): Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 50 mCi/m\^2 of 177-Lu.
- Cohort 4, 60 mCi/m^2 177-Lu-DOTA-cG250 (Type: EXPERIMENTAL): Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 60 mCi/m\^2 of 177-Lu.
- Cohort 5, 70 mCi/m^2 177-Lu-DOTA-cG250 (Type: EXPERIMENTAL): Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 70 mCi/m\^2 of 177-Lu.
- Cohort 6, 65 mCi/m^2 177-Lu-DOTA-cG250 (Type: EXPERIMENTAL): Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 65 mCi/m\^2 of 177-Lu.

Based on this trial design, predict the completion outcome and termination type (if applicable).